股票新闻将Abeona Therapeutics (NASDAQ:ABEO) 从卖出升级为持有,并提供其他分析师的目标价格更新和评级变化. StockNews upgraded Abeona Therapeutics (NASDAQ:ABEO) from Sell to Hold, with target price updates and rating changes from other analysts.
股票新闻将Abeona Therapeutics (NASDAQ:ABEO) 从卖出升级为持有,而Stifel Nicolaus则以21.00美元的目标发布了买入评级,Cantor Fitzgerald将其目标从28.00美元降至21.00美元并给出了超重评级,HC Wainwright重申了以15.00美元的目标购买评级. StockNews upgraded Abeona Therapeutics (NASDAQ:ABEO) from Sell to Hold, while Stifel Nicolaus issued a Buy rating with a $21.00 target, Cantor Fitzgerald lowered its target from $28.00 to $21.00 and gave an Overweight rating, and HC Wainwright reiterated a Buy rating with a $15.00 target. Abeona 治疗学是临床阶段的生物制药合作项目,重点是稀有疾病的基因治疗;机构投资者拥有其存量的80.56%。 Abeona Therapeutics, a clinical-stage biopharmaceutical co, focuses on gene therapy for rare diseases; institutional investors own 80.56% of its stock.